Abstract
In this essay I explore the notion that corporations are moral agents that may aspire to virtuosity. If corporations must lose their innocence as natural moral agents do, then they too may enter a moral life cycle. Since loss of innocence may result in a sense of care about one’s behavior, one may expect corporations to manifest the affect of care. In my view the 18 corporations that made the Built-to-Last list exemplify how corporations do care about their core ideology. Using Merck and Company, Inc. as an example I discuss one way that ethicists may turn the care of corporations about their mission statement to the advantage of the entire moral community.
For those corporations that qualify as corporate persons I assume that corporate virtuosity is a good that may be publicly recognized, and it may be valuable to corporations. I also assume that corporate virtuosity is a status that is achieved over time through testing and by comparison with their peers. For instance, some corporations do seem to have the virtuosity of being in the top tier of the best places to work. Likewise when some corporations ask their shareholders to vote against a shareholder resolution on ethical conduct, management may argue that the corporation follows its own ethical code of conduct. I want to suggest that when corporations set forth ethical guidelines for behavior in their mission statement they are creating a program for the development of corporate virtuosity. How corporations respond to ethical crises and how they aspire to excellence will determine whether they are making progress toward corporate virtuosity or if not.
“Every virtue or excellence both brings into good condition the thing of which it is the excellence and makes the work of that thing be done well”
– Aristotle
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aristotle. Edited by McKeon, R. (1941). The basic works of Aristotle. New York: Random House.
Barrett, J. (2005). Can Merck survive Vioxx? Newsweek, 146(9–10), 42.
Barron’s Dictionary of Finance and Investment Terms, S.v., Going-concern value.
Citizens Funds’. (2004). Annual report and supplemental commentary. Portsmouth: Citizens Securities.
Collins, J. C., & Porras, J. I. (1994). Built to last. New York: Harper Collins.
Cox-2 selective (Includes Bextra, Celebrex, and Vioxx) and non-selective non-steriodal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/cder/drug/infopage/COX2/defalult.htm
Fortune. (2013, May 20). Chart. F1–31.
Frazier, KC. (2013). Letter to shareholders. In Merck and co. Inc. (2013) Annual report.
French, P. (1979). The corporation as a moral person. American Philosophical Quarterly, 16(3), 207–215.
French, P. (1992). Responsibility matters. Lawrence: University Press of Kansas.
Haney, M. (2004). Corporate loss of innocence for the sake of accountability. Journal of Social Philosophy, 35(3), 391–412.
Merck and Co., Inc. (2005). Annual report.
Merck and Company, Inc., Proxy statement for 2005.
Merck and Co., Inc. (2013). Form 10-K.
Mission statement. http://www.merck.com/about/mission_print.html
Wilson, P. E. (1993). Corporate scapegoating. Journal of Business Ethics, 12, 779–784.
Wilson, P. E. (1996). Sanity and irresponsibility. Philosophy, Psychiatry, Psychology, 3(4), 293–302.
Young, D. (2005). FDA’s drug safety initiative: Resolutions or more questions? American Journal of Health-Systems Pharmacy, 62, 1333–1336.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Wilson, P.E. (2015). The Lure of Corporate Virtue. In: Idowu, S., Frederiksen, C., Mermod, A., Nielsen, M. (eds) Corporate Social Responsibility and Governance. CSR, Sustainability, Ethics & Governance. Springer, Cham. https://doi.org/10.1007/978-3-319-10909-1_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-10909-1_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-10908-4
Online ISBN: 978-3-319-10909-1
eBook Packages: Business and EconomicsBusiness and Management (R0)